NP 61

Drug Profile

NP 61

Alternative Names: NP 0361; NP-61

Latest Information Update: 07 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuropharma
  • Class Antidementias; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 18 Dec 2012 Noscira is in liquidation
  • 18 Dec 2012 Discontinued - Phase-I for Alzheimer's disease in Ireland (PO)
  • 10 Mar 2009 Noscira is seeking partnership opportunities for further development and commercialisation of NP 61 worldwide, except the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top